Search clinical trials for: PRT060128

Total 3 results

Portola Pharmaceuticals

Terminated

Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI (ERASE-MI)

Myocardial Infarction

United States, Canada
Portola Pharmaceuticals
Novartis

Terminated

Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

United States
Portola Pharmaceuticals

Completed

A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI (INNOVATE-PCI)

Percutaneous Coronary Intervention

United States, Austria, Canada, Germany, Poland

3

Subscribe